BridgeBio Oncology Therapeutics Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -2.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.55 | $-0.71 | -29.1% | Miss | |
| Q1 FY26 | $-0.51 | $-0.53 | -3.9% | Miss | |
| Q4 FY25 | $-0.67 | $-0.49 | +26.9% | Beat | |
| Q3 FY25 | not reported | $-1.03 | not reported | not reported |
Back to BBOT overview · BBOT holders · BBOT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.